Mannose
9 benefits mapped to clinical evidence across supplements.
Dose per serving from products
510 products in our catalogue print how much Mannose a serving holds.
Most common: 500 mg to 1 g, 26% of 510 products.
| Dose per serving | Products |
|---|---|
| 25 mg or less | 15 |
| 25 mg to 50 mg | 43 |
| 50 mg to 100 mg | 83 |
| 100 mg to 250 mg | 71 |
| 250 mg to 500 mg | 68 |
| 500 mg to 1 g | 133 |
| 1 g to 2.5 g | 90 |
| over 2.5 g | 7 |
Benefit Evidence
Less UTI, better comfort
Faster symptom relief
Less UTI, more comfort
-46% recurrence
UTI relief, fewer recurrences
+88.6% cure; -60.8% recurrences
UTI fewer, comfort better
Pain/symptoms lower, -21% UTI
Less UTI, better comfort
Faster symptom relief
Less UTI, more comfort
-46% recurrence
UTI relief, fewer recurrences
+88.6% cure; -60.8% recurrences
UTI fewer, comfort better
Pain/symptoms lower, -21% UTI
Research sources
Urinary comfort (12)
- [Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]
PubMed ID: 29521263
Randomized double‑blind trial where Manosar® (contains D‑mannose) significantly reduced recurrent UTI incidence vs comparator.
- D-Mannose Plus Saccharomyces boulardii to Prevent Urinary Tract Infections and Discomfort after Cystoscopy: A Single-Center Prospective Randomized Pilot Study
PubMed ID: 37374369
Randomized pilot: D‑mannose + S. boulardii reduced post‑cystoscopy bacteriuria and urinary symptom burden.
- [Experience with UroBest in patients with acute cystitis]
PubMed ID: 39563582
Adjunct treatment reduced pain scores in acute cystitis (direct evidence for reducing urinary discomfort; not mannose‑specific).
- Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery
PubMed ID: 31674202
Supplement containing D‑mannose improved urinary filling symptom scores after prolapse surgery (statistically significant).
- A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections
PubMed ID: 36621376
D‑mannose‑based supplement produced marked clinical symptom resolution in E. coli UTI.
- Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C improves sexual and urinary symptoms in participants with recurrent urinary tract infections: a randomized crossover trial
PubMed ID: 38721680
Participants on a regimen including D‑mannose reported earlier urinary symptom improvements after additional treatment; attribution to D‑mannose uncertain.
- Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study
PubMed ID: 20398248
Urinary anti-adhesion activity from cranberry peaked at ~6 h and persisted partially at 24 h, suggesting short-term functional benefit.
- A randomized, double-blind, placebo-controlled trial to assess the bacterial anti-adhesion effects of cranberry extract beverages
PubMed ID: 25723356
Urine anti-adhesion activity after cranberry suggests potential for prevention.
- [Evaluation of the effects of a natural dietary supplement with cranberry, Noxamicina® and D-mannose in recurrent urinary infections in perimenopausal women]
PubMed ID: 28608666
Product including D-mannose used for symptomatic remission in recurrent cystitis represents a non-antibiotic alternative.
- Large study (283 women) on the effectiveness of Manosar®: 2 g of d-mannose + 140 mg of proanthocyanidins (PAC), of prolonged release
PubMed ID: 32633244
Randomized trial: prolonged‑release D‑mannose + PAC significantly reduced recurrent E. coli UTIs versus PAC alone — strong evidence for prevention.
- D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial
PubMed ID: 23633128
Direct randomized evidence: daily D‑mannose powder markedly lowered recurrent UTI incidence vs no prophylaxis (strong, direct support).
- Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation
PubMed ID: 28403598
Direct randomized comparison found a D‑mannose‑containing oral regimen performed similarly to antibiotics for short‑term prophylaxis—strong support as a non‑antibiotic option in that context.
Antimicrobial (8)
- Large study (283 women) on the effectiveness of Manosar®: 2 g of d-mannose + 140 mg of proanthocyanidins (PAC), of prolonged release
PubMed ID: 32633244
Clinical reduction in E. coli recurrences with D-mannose+PAC supports a role in preventing bacterial colonization/adhesion.
- Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation
PubMed ID: 28403598
Similar short‑term infection rates compared with antibiotics imply the regimen (which included D‑mannose) may prevent bacterial colonization post‑procedure.
- D-Mannose Plus Saccharomyces boulardii to Prevent Urinary Tract Infections and Discomfort after Cystoscopy: A Single-Center Prospective Randomized Pilot Study
PubMed ID: 37374369
Zero positive cultures after cystoscopy in treatment arm suggests an effect on infection presence (indirect evidence consistent with anti‑adhesive activity of D‑mannose).
- D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial
PubMed ID: 23633128
Clinical reduction in recurrent UTIs implies fewer bacterial colonization events; supports the notion that D‑mannose interferes with bacterial adherence (clinical evidence).
- [Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]
PubMed ID: 29521263
Lower recurrence rates with the D‑mannose‑containing product are consistent with reduced bacterial reinfection/colonization, though multipart formulation limits specific attribution.
- A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections
PubMed ID: 36621376
Bacteriological resolution rates were very high (85.7% day 6, 100% day 35) in the multicomponent D‑mannose product arm, strongly suggesting bacterial clearance though multiple agents were present.
- Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study
PubMed ID: 20398248
Cranberry PACs produced a strong, dose-dependent urinary anti-adhesion effect (mechanistic evidence that bacteria are less able to adhere).
- A randomized, double-blind, placebo-controlled trial to assess the bacterial anti-adhesion effects of cranberry extract beverages
PubMed ID: 25723356
Cranberry intake increased urine anti-adhesion activity ex vivo versus placebo, suggesting reduced bacterial adhesion.
Daily comfort (10)
- [Evaluation of the effects of a natural dietary supplement with cranberry, Noxamicina® and D-mannose in recurrent urinary infections in perimenopausal women]
PubMed ID: 28608666
High rates of symptom remission with D-mannose-containing product imply improved day-to-day comfort.
- Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C improves sexual and urinary symptoms in participants with recurrent urinary tract infections: a randomized crossover trial
PubMed ID: 38721680
Earlier improvements in urinary and sexual symptom scores in the intervention group suggest better QoL aspects; D‑mannose contribution unclear.
- A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections
PubMed ID: 36621376
D‑mannose‑based supplement rapidly improved UTI symptoms and bacteriological clearance — likely translates into daily comfort gains.
- D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial
PubMed ID: 23633128
Fewer recurrent UTIs implies improved daily comfort and fewer symptomatic episodes.
- Large study (283 women) on the effectiveness of Manosar®: 2 g of d-mannose + 140 mg of proanthocyanidins (PAC), of prolonged release
PubMed ID: 32633244
By reducing infection recurrence, D-mannose+PAC plausibly improves quality of life though QoL was not the primary endpoint.
- Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation
PubMed ID: 28403598
Prevention of procedure-related UTIs supports better short-term comfort after urodynamic testing.
- [Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]
PubMed ID: 29521263
Fewer recurrent UTIs with Manosar® would be expected to improve day‑to‑day comfort for affected individuals.
- D-Mannose Plus Saccharomyces boulardii to Prevent Urinary Tract Infections and Discomfort after Cystoscopy: A Single-Center Prospective Randomized Pilot Study
PubMed ID: 37374369
Reduced urinary symptoms and pain after intervention likely translate into improved short‑term daily comfort.
- [Experience with UroBest in patients with acute cystitis]
PubMed ID: 39563582
Reported QoL and pain improvements in acute cystitis with adjunct treatment (supports daily comfort while symptomatic).
- Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery
PubMed ID: 31674202
Postoperative patients reported better urinary filling symptoms with a supplement including D-mannose, suggesting improved daily comfort.
Illness recovery (6)
- D-Mannose Plus Saccharomyces boulardii to Prevent Urinary Tract Infections and Discomfort after Cystoscopy: A Single-Center Prospective Randomized Pilot Study
PubMed ID: 37374369
D‑mannose + S. boulardii improved symptoms and pain after cystoscopy (minor urinary irritation) and reduced bacteriuria.
- [Experience with UroBest in patients with acute cystitis]
PubMed ID: 39563582
Adjunct regimen including UroBest improved pain scores and QoL in acute cystitis (evidence for promoting recovery/relief).
- A Randomized Controlled Trial Comparing a New D-Mannose-based Dietary Supplement to Placebo for the Treatment of Uncomplicated Escherichia coli Urinary Tract Infections
PubMed ID: 36621376
D‑mannose supplement markedly improved clinical symptom resolution in acute UTI, consistent with promoting recovery from urinary irritation.
- D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial
PubMed ID: 23633128
Lower recurrence and likely fewer symptomatic episodes suggest enhanced recovery/less irritation.
- Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation
PubMed ID: 28403598
Peri‑procedure D‑mannose regimen prevented UTIs after urodynamic testing — can aid recovery from procedure-related irritation/infection.
- [Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with Proanthocyanidin (PAC), versus isolate PAC, in the management of a series of women with recurrent urinary infections.]
PubMed ID: 29521263
Reduced recurrent UTIs implies fewer episodes of urinary irritation and improved recovery over time.
Immune support (4)
- Effect of pericardial blood processing on postoperative inflammation and the complement pathways
PubMed ID: 18222258
Directly measures mannose‑binding lectin (MBL) activity during CPB—strong link to innate immune lectin pathway.
- Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial
PubMed ID: 34391418
MBL (a mannose-recognizing lectin) concentrations linked to COPD exacerbation risk — relevant to mannose-related immune pathways.
- A Rare Genetic Defect of MBL2 Increased the Risk for Progression of IgA Nephropathy
PubMed ID: 30967869
MBL2 loss-of-function genotype (MBL deficiency) strongly affects renal outcomes — demonstrates clinical importance of mannose-binding lectin in immunity.
- An Assessment of the Glyconutrient Ambrotose™ on Immunity, Gut Health, and Safety in Men and Women: A Placebo-Controlled, Double-Blind, Randomized Clinical Trial
PubMed ID: 32545396
Ambrotose (mannose-containing polysaccharides) produced modest immune shifts (monocytes, IL‑10).
Metabolism (2)
- Coffee mannooligosaccharides, consumed as part of a free-living, weight-maintaining diet, increase the proportional reduction in body volume in overweight men
PubMed ID: 20861211
Smaller MOS trial showed modest reductions in adiposity—supports metabolic effects.
- A weight-loss diet including coffee-derived mannooligosaccharides enhances adipose tissue loss in overweight men but not women
PubMed ID: 21938072
MOS enhanced weight and adipose loss in men vs placebo—direct metabolic benefit.
Wellbeing (2)
- A weight-loss diet including coffee-derived mannooligosaccharides enhances adipose tissue loss in overweight men but not women
PubMed ID: 21938072
Coffee‑derived mannooligosaccharides (MOS) significantly increased weight/fat loss in men—clinically meaningful wellbeing benefit.
- Coffee mannooligosaccharides, consumed as part of a free-living, weight-maintaining diet, increase the proportional reduction in body volume in overweight men
PubMed ID: 20861211
Smaller MOS trial showed modest reductions in body volume/adiposity—supports metabolic wellbeing.
Nerve health (1)
- Large study (283 women) on the effectiveness of Manosar®: 2 g of d-mannose + 140 mg of proanthocyanidins (PAC), of prolonged release
PubMed ID: 32633244
Reduction in recurrent infections with D-mannose+PAC suggests maintenance of urinary microbial/clinical balance (indirect evidence).
Energy & Fatigue (1)
- A weight-loss diet including coffee-derived mannooligosaccharides enhances adipose tissue loss in overweight men but not women
PubMed ID: 21938072
MOS led to greater weight/fat loss in men—could favorably influence energy balance.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Mannose
Search all819 products whose verified label declares Mannose — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.